Tag: professor

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

The strategic partnership aligns American motorsports, military leadership, and financial innovation to introduce TAP's newest advisory initiatives.

WATERTOWN, Mass. and CINCINNATI, June 18, 2026 (GLOBE NEWSWIRE) -- Constantiam Biosciences and Cincinnati Children's today announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3).

LIVERMORE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Inertia Enterprises, the commercial fusion energy company, today announced the formation of its Science and Technology Advisory Board (STAB). The newly formed advisory board is an independent group of the world's foremost experts in fusion plasma physics, high-energy laser systems, large-scale program execution, target fabrication, and nuclear materials science. Its purpose is to provide rigorous, independent technical assessment across Inertia's physics, target, laser, and power plant development programs as the company prepares to deliver grid-scale fusion energy in the 2030s.

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.